NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that reached the public markets through its merger with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2018. The business combination closed in late 2020, bringing NRX's pipeline of critical-care treatments — including experimental therapies targeting COVID-19-related respiratory failure and treatment-resistant bipolar depression — to the Nasdaq. The company filed an 8-K with the SEC on March 22, 2021, as part of its ongoing post-merger public reporting obligations. For comprehensive filing histories, deal timelines, and real-time SPAC intelligence on NRXP and hundreds of other transactions, sign up for full data access at SpacDesk.